Skip to content
Sign in
Artwork for Medical Device Global Market Access
Medical Device Global Market Access · August 18 · 5 min

CMS RAPID Coverage Pathway: Breakthrough Device Reimbursement Changes

The U.S. Centers for Medicare & Medicaid Services (CMS) has introduced a major policy change with the new Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. Announced in a procedural notice on August 7, 2026, this pathway aims to significantly reduce the delay between FDA market authorization and a national Medicare coverage decision for eligible FDA Breakthrough-designated devices. This episode breaks down the eligibility criteria for Class II and III devices, the plan for simultaneous FDA and CMS decisions, and the critical public comment deadline of October 10, 2026. We explore what this means for innovative device manufacturers and provide practical steps for navigating this new reimbursement landscape. Key Questions: - What is the new CMS RAPID Coverage Pathway and what problem does it solve? - How does the RAPID pathway propose to align FDA authorization with Medicare coverage decisions? - Which specific types of medical devices are eligible for this expedited reimbursement program? - What was announced in the CMS procedural notice on August 7, 2026? - What is the significance of the October 10, 2026 deadline for public comments? - How should manufacturers adjust their evidence generation strategy to meet both FDA and CMS requirements? - What are the key differences between the FDA's 'safe and effective' standard and CMS's 'reasonable and necessary' criteria? - What practical steps should regulatory and market access teams take to prepare for the RAPID pathway? Sources: - https://www.cms.gov/newsroom/fact-sheets/regulatory-alignment-predictable-immediate-device-coverage-pathway-cms-3487-nc-procedural-notice - https://www.aha.org/news/headline/2026-08-07-cms-releases-notice-pathway-expediting-access-certain-medical-devices-medicare - https://www.hklaw.com/en/insights/publications/2026/08/rapid-coverage-pathway-comments-due-october-10-2026 - https://www.acrinews.org/archives/2026/August/CMS-Proposes-RAPID-Pathway-for-Faster-Device-Coverage - https://www.managedhealthcareexecutive.com/view/cms-and-fda-propose-rapid-medicare-coverage-pathway-for-breakthrough-devices - https://www.worktraining.com/news/cms-proposes-rapid-pathway-for-accelerated-medicare-coverage-of-innovative-medical-devices/ - https://www.federalregister.gov/documents/2026/08/11/2026-17389/medicare-program-regulatory-alignment-for-predictable-and-immediate-device-rapid-coverage-pathway How Pure Global can help: Navigating complex reimbursement pathways like the CMS RAPID program requires a strategic approach to both regulatory approval and market access. Pure Global provides end-to-end consulting for MedTech companies, developing efficient regulatory strategies that align with reimbursement requirements from the earliest stages. Our experts help you prepare for parallel engagement with bodies like the FDA and CMS, ensuring your technical dossier and clinical evidence meet the standards of multiple authorities. By leveraging our global network and advanced AI tools, we streamline dossier preparation and submission, helping you access markets faster. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

0:00-5:26
Play in

transcript

No transcript — this publisher did not publish one.

show notes

The U.S. Centers for Medicare & Medicaid Services (CMS) has introduced a major policy change with the new Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. Announced in a procedural notice on August 7, 2026, this pathway aims to significantly reduce the delay between FDA market authorization and a national Medicare coverage decision for eligible FDA Breakthrough-designated devices. This episode breaks down the eligibility criteria for Class II and III devices, the plan for simultaneous FDA and CMS decisions, and the critical public comment deadline of October 10, 2026. We explore what this means for innovative device manufacturers and provide practical steps for navigating this new reimbursement landscape.

Key Questions:
- What is the new CMS RAPID Coverage Pathway and what problem does it solve?
- How does the RAPID pathway propose to align FDA authorization with Medicare coverage decisions?
- Which specific types of medical devices are eligible for this expedited reimbursement program?
- What was announced in the CMS procedural notice on August 7, 2026?
- What is the significance of the October 10, 2026 deadline for public comments?
- How should manufacturers adjust their evidence generation strategy to meet both FDA and CMS requirements?
- What are the key differences between the FDA's 'safe and effective' standard and CMS's 'reasonable and necessary' criteria?
- What practical steps should regulatory and market access teams take to prepare for the RAPID pathway?

Sources:
- https://www.cms.gov/newsroom/fact-sheets/regulatory-alignment-predictable-immediate-device-coverage-pathway-cms-3487-nc-procedural-notice
- https://www.aha.org/news/headline/2026-08-07-cms-releases-notice-pathway-expediting-access-certain-medical-devices-medicare
- https://www.hklaw.com/en/insights/publications/2026/08/rapid-coverage-pathway-comments-due-october-10-2026
- https://www.acrinews.org/archives/2026/August/CMS-Proposes-RAPID-Pathway-for-Faster-Device-Coverage
- https://www.managedhealthcareexecutive.com/view/cms-and-fda-propose-rapid-medicare-coverage-pathway-for-breakthrough-devices
- https://www.worktraining.com/news/cms-proposes-rapid-pathway-for-accelerated-medicare-coverage-of-innovative-medical-devices/
- https://www.federalregister.gov/documents/2026/08/11/2026-17389/medicare-program-regulatory-alignment-for-predictable-and-immediate-device-rapid-coverage-pathway

How Pure Global can help:
Navigating complex reimbursement pathways like the CMS RAPID program requires a strategic approach to both regulatory approval and market access. Pure Global provides end-to-end consulting for MedTech companies, developing efficient regulatory strategies that align with reimbursement requirements from the earliest stages. Our experts help you prepare for parallel engagement with bodies like the FDA and CMS, ensuring your technical dossier and clinical evidence meet the standards of multiple authorities. By leveraging our global network and advanced AI tools, we streamline dossier preparation and submission, helping you access markets faster. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

more episodes

All episodes